BR0013834A - Composições e métodos para estimular a secreção de citoquinas e induzir uma resposta imunológica - Google Patents

Composições e métodos para estimular a secreção de citoquinas e induzir uma resposta imunológica

Info

Publication number
BR0013834A
BR0013834A BR0013834-7A BR0013834A BR0013834A BR 0013834 A BR0013834 A BR 0013834A BR 0013834 A BR0013834 A BR 0013834A BR 0013834 A BR0013834 A BR 0013834A
Authority
BR
Brazil
Prior art keywords
nucleic acid
lipid
conveniently
particles
modified
Prior art date
Application number
BR0013834-7A
Other languages
English (en)
Inventor
Sean C Semple
Troy O Harasym
Sandra K Klimuk
Ljiljiana D Kojic
Jonathan L Bramson
Barbara Mui
Michael J Hope
Original Assignee
Inex Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inex Pharmaceuticals Corp filed Critical Inex Pharmaceuticals Corp
Publication of BR0013834A publication Critical patent/BR0013834A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"COMPOSIçõES E MéTODOS PARA ESTIMULAR A SECREçãO DE CITOQUINAS E INDUZIR UMA RESPOSTA IMUNOLóGICA". As partículas de lipídeo-ácido nucléico podem proporcionar benefícios terapêuticos, mesmo quando o ácido nucléico não é complementar em relação às seq³ências de codificação dentro das células alvo. Descobriu-se que as partículas de lipídeo-ácido nucléico, incluindo aquelas contendo oligodeoxinucleotídeos que não são específicos para uma determinada seq³ência, podem ser utilizadas para estimular a secreção de citoquinas, aumentando assim a resposta global de um mamífero tratado desta forma. Além disso, a resposta imunológica a antígenos alvo específicos pode ser induzida por meio da administração de uma molécula antigênica em associação com partículas de lipídeo contendo oligodeoxinucleotídeos que não são específicos para uma determinada seq³ência. o ácido nucléico que está incluído na partícula de lipídeo-ácido nucléico pode ser um fosfodiéster (ou seja, um oligodeoxinucleotídeo consistindo em resíduos de nucleotídeo unidos por meio de ligações fosfodiéster) ou um ácido nucléico modificado que inclui fosforotioato ou outras ligações modificadas, e pode convenientemente ser um que não seja complementar em relação ao genoma humano, de maneira tal que atua para proporcionar estímulo imunológico de forma independente das interações de pareamento de bases convencionais entre o ácido nucléico e ácidos nucléicos do mamífero tratado em particular, o ácido nucléico pode convenientemente conter um tema estimulante de imunidade tal como um tema CpG, ou uma seq³ência palindrómica estimulante de imunidade. O lipídeo catiónico incluído nas partículas de ácido nucléico pode ser convenientemente selecionado do grupo composto por DODAP, DODMA, DMDMA, DOTAP, DC-Chol, DDAB, DODAC, DMRIE, DOSPA e DOGS. Além disso, a partícula de lipídeo pode convenientemente conter um lipídeo limitador de agregação modificado tal como um lipídeo-PEG, lipídeo-PAO ou gangliosídeo.
BR0013834-7A 1999-08-27 2000-08-28 Composições e métodos para estimular a secreção de citoquinas e induzir uma resposta imunológica BR0013834A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15121199P 1999-08-27 1999-08-27
US17640600P 2000-01-13 2000-01-13
PCT/CA2000/001013 WO2001015726A2 (en) 1999-08-27 2000-08-28 Compositions for stimulating cytokine secretion and inducing an immune response

Publications (1)

Publication Number Publication Date
BR0013834A true BR0013834A (pt) 2002-04-23

Family

ID=26848421

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0013834-7A BR0013834A (pt) 1999-08-27 2000-08-28 Composições e métodos para estimular a secreção de citoquinas e induzir uma resposta imunológica

Country Status (15)

Country Link
EP (1) EP1212085B1 (pt)
JP (1) JP2003509341A (pt)
KR (1) KR100737980B1 (pt)
CN (1) CN100368020C (pt)
AT (1) ATE376838T1 (pt)
AU (1) AU780535B2 (pt)
BR (1) BR0013834A (pt)
CA (1) CA2382611A1 (pt)
CZ (1) CZ20021029A3 (pt)
DE (1) DE60036950T2 (pt)
HU (1) HUP0202327A3 (pt)
IL (1) IL148359A0 (pt)
MX (1) MXPA02002107A (pt)
PL (1) PL354879A1 (pt)
WO (1) WO2001015726A2 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
FR2814958B1 (fr) * 2000-10-06 2003-03-07 Aventis Pasteur Composition vaccinale
CA2430691A1 (en) 2000-12-27 2002-07-04 Dynavax Technologies Corporation Immunomodulatory polynucleotides and methods of using the same
EP1404873B1 (en) 2001-06-21 2013-05-22 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same
WO2003000232A2 (en) * 2001-06-25 2003-01-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for preparation of vesicles loaded with immunostimulator y oligodeoxynucleotides
AU2002326561B2 (en) 2001-08-07 2008-04-03 Dynavax Technologies Corporation Immunomodulatory compositions, formulations, and methods for use thereof
WO2003015816A1 (en) * 2001-08-10 2003-02-27 Dynavax Technologies Corporation Immunomodulatory oligonucleotide formulations and methods for use thereof
US20030119774A1 (en) * 2001-09-25 2003-06-26 Marianna Foldvari Compositions and methods for stimulating an immune response
AU2002340662B2 (en) * 2001-11-07 2008-07-03 Tekmira Pharmaceuticals Corporation Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
ES2258652T3 (es) 2001-11-29 2006-09-01 Pfizer Products Inc. Sales de succinato de 5,8,14-triazatetraciclo(10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de los mismos.
WO2003094829A2 (en) * 2002-05-10 2003-11-20 Inex Pharmaceuticals Corporation Pathogen vaccines and methods for using the same
ATE411815T1 (de) * 2002-05-10 2008-11-15 Tekmira Pharmaceuticals Corp Methylierte immunstimulierende oligodeoxynukleotide und verfahren zu deren verwendung
CA2752143C (en) 2002-05-15 2014-09-23 Sutter West Bay Hospitals Delivery of nucleic acid-like compounds
KR20050052467A (ko) 2002-08-12 2005-06-02 다이나박스 테크놀로지 코퍼레이션 면역조절 조성물, 이의 제조방법 및 이의 이용방법
PT1992635E (pt) 2002-12-23 2012-03-20 Dynavax Tech Corp Oligonucleótidos de sequência imunoestimuladora e métodos de utilização dos mesmos
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
CA2542099A1 (en) * 2003-10-11 2005-04-21 Inex Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
WO2005060330A2 (en) * 2003-12-22 2005-07-07 Statens Serum Institut Freeze-dried vaccine adjuvant
NZ561144A (en) 2005-03-04 2009-09-25 Dynavax Tech Corp Vaccines comprising oligonucleotides having immunostimulatory sequences (ISS) wherein the ISS are conjugated to antigens and stabilized by buffer conditions and further excipients
US9006487B2 (en) 2005-06-15 2015-04-14 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
CN100418583C (zh) * 2006-02-21 2008-09-17 朱鸿飞 预防和治疗乳腺炎的药物组合物
WO2009086558A1 (en) 2008-01-02 2009-07-09 Tekmira Pharmaceuticals Corporation Improved compositions and methods for the delivery of nucleic acids
CN102119217B (zh) 2008-04-15 2015-06-03 普洛体维生物治疗公司 用于核酸递送的新型制剂
ES2475065T3 (es) 2008-10-09 2014-07-10 Tekmira Pharmaceuticals Corporation Aminol�pidos mejorados y métodos para la administración de ácidos nucleicos
WO2010062322A2 (en) * 2008-10-27 2010-06-03 Massachusetts Institute Of Technology Modulation of the immune response
CN104910025B (zh) 2008-11-07 2019-07-16 麻省理工学院 氨基醇类脂质和其用途
EP3243504A1 (en) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
CA2760706C (en) 2009-05-05 2019-08-06 Alnylam Pharmaceuticals, Inc. Methods of delivering oligonucleotides to immune cells
SG10201402054UA (en) 2009-05-05 2014-09-26 Muthiah Manoharan Lipid compositions
TR201811076T4 (tr) 2009-06-10 2018-08-27 Arbutus Biopharma Corp Geliştirilmiş lipit formulasyonu.
IL292615B2 (en) 2009-07-01 2023-11-01 Protiva Biotherapeutics Inc Nucleic acid-lipid particles, preparations containing them and their uses
EP2609135A4 (en) 2010-08-26 2015-05-20 Massachusetts Inst Technology POLY (BETA-AMINO ALCOHOLS), THEIR PREPARATION AND USES THEREOF
WO2012135025A2 (en) 2011-03-28 2012-10-04 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
KR102384791B1 (ko) 2012-02-24 2022-04-08 아뷰터스 바이오파마 코포레이션 트리알킬 양이온성 지질 및 그의 사용 방법
BR112014029247A2 (pt) * 2012-05-23 2017-06-27 Univ Ohio State nanopartícula de lipídio, composição farmacêutica, método para fazer uma nanopartícula de lipído, produto, método de tratamento de um distúrbio, e sistema de entrega
CA2884870C (en) 2012-08-13 2022-03-29 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
WO2014179562A1 (en) 2013-05-01 2014-11-06 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
EP3164379A1 (en) 2014-07-02 2017-05-10 Massachusetts Institute of Technology Polyamine-fatty acid derived lipidoids and uses thereof
CN112423766A (zh) * 2018-07-19 2021-02-26 一般财团法人阪大微生物病研究会 含有A型CpG寡脱氧核糖核苷酸的脂质颗粒
EP3892260A1 (en) * 2020-04-10 2021-10-13 Bayer Animal Health GmbH Immunostimulatory compositions based on liposomes with zwiterionic and cationic lipids
TW202224689A (zh) * 2020-12-28 2022-07-01 財團法人工業技術研究院 免疫刺激性脂質複合體、包含免疫刺激性脂質複合體的醫藥組合物以及其用途
WO2023144798A1 (en) 2022-01-31 2023-08-03 Genevant Sciences Gmbh Ionizable cationic lipids for lipid nanoparticles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ268146A (en) * 1994-04-12 1997-10-24 Liposome Co Inc Liposome compositions and medicinal uses
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE420171T1 (de) * 1994-07-15 2009-01-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
DK1005368T3 (da) * 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
US6287591B1 (en) * 1997-05-14 2001-09-11 Inex Pharmaceuticals Corp. Charged therapeutic agents encapsulated in lipid particles containing four lipid components
JP4101888B2 (ja) * 1997-06-06 2008-06-18 ダイナバックス テクノロジーズ コーポレイション 免疫刺激オリゴヌクレオチド、その組成物およびその使用方法
AU8525098A (en) * 1997-07-24 1999-02-16 Inex Pharmaceuticals Corporation Liposomal compositions for the delivery of nucleic acid catalysts

Also Published As

Publication number Publication date
PL354879A1 (en) 2004-03-08
JP2003509341A (ja) 2003-03-11
DE60036950T2 (de) 2008-08-07
CA2382611A1 (en) 2001-03-08
WO2001015726A3 (en) 2001-07-26
HUP0202327A3 (en) 2004-07-28
DE60036950D1 (de) 2007-12-13
HUP0202327A2 (en) 2002-10-28
KR20020068500A (ko) 2002-08-27
KR100737980B1 (ko) 2007-07-12
CN100368020C (zh) 2008-02-13
ATE376838T1 (de) 2007-11-15
EP1212085B1 (en) 2007-10-31
CN1501811A (zh) 2004-06-02
IL148359A0 (en) 2002-09-12
CZ20021029A3 (cs) 2002-08-14
AU6813900A (en) 2001-03-26
WO2001015726A2 (en) 2001-03-08
AU780535B2 (en) 2005-03-24
EP1212085A2 (en) 2002-06-12
MXPA02002107A (es) 2003-08-20

Similar Documents

Publication Publication Date Title
BR0013834A (pt) Composições e métodos para estimular a secreção de citoquinas e induzir uma resposta imunológica
JP4989225B2 (ja) 核酸親油性接合体
US8188254B2 (en) C-class oligonucleotide analogs with enhanced immunostimulatory potency
EP2197488B1 (en) Immune stimulatory oligonucleotide analogs containing modified sugar moieties
JP2007531746A (ja) Ｉｌ−１０応答を誘導するための免疫活性化核酸
US20100285041A1 (en) Class A Oligonucleotides with Immunostimulatory Potency
JP2010536787A (ja) Ｔｏｌｌ様受容体モジュレータ
WO2007117686A2 (en) Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8
MXPA06014915A (es) Multimeros oligonucleotidicos inmunoestimuladores.
Gürsel et al. Immunoadjuvant action of plasmid DNA in liposomes
JP2007531510A (ja) 短い免疫調節性オリゴヌクレオチド
BR112015016420B1 (pt) Composto de oligonucleotídeo imunorregulatório, composição farmacêutica e uso do composto iro ou da composição farmacêutica
WO2000040692A2 (en) Methods and compositions for delivering nucleic acids
JP2005525414A5 (pt)
JP2007151536A (ja) 免疫刺激力が増強されたｃ−クラスのオリゴヌクレオチドアナログ
MXPA06004891A (en) C-class oligonucleotide analogs with enhanced immunostimulatory potency

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]